Melanoma research rarely stays still. New trial data, updated staging criteria, fresh perspectives on immunotherapy resistance — the field moves at a pace that can be hard to keep up with if you're not embedded in it every day. This space gathers the threads that matter: findings from EORTC-led studies, clinical practice shifts across European centres, and the quieter conversations happening between researchers, oncologists, and patients trying to make sense of a diagnosis that has changed dramatically over the past decade.
It's written for a mixed audience on purpose — clinicians looking for a digestible summary of trial outcomes, junior researchers scanning for context before diving into a paper, and patients or caregivers who want more than a glossary entry but less than a full journal article. 🩺
Trial Insights
Plain-language breakdowns of EORTC melanoma trials — what worked, what didn't, and what it means for treatment protocols.
Biomarkers & Staging
How molecular profiling and updated AJCC staging are reshaping risk assessment and follow-up decisions.
Collaborative Practice
Notes from multidisciplinary tumour boards and cross-border coordination among European melanoma units.
Patient-Reported Outcomes
Why quality-of-life data is finally being treated as evidence, not an afterthought, in trial design.
Pick a thread that interests you and follow it — the details usually reward the curiosity.